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Abstract Cell death in bacteria can be triggered by
activation of self-inflicted molecular mechanisms. Patho-
genic bacteria often make use of suicide mechanisms in
which the death of individual cells benefits survival of the
population. Important elements for programmed cell death
in bacteria are proteinaceous toxin–antitoxin systems.
While the toxin generally resides dormant in the bacterial
cytosol in complex with its antitoxin, conditions such as
impaired de novo synthesis of the antitoxin or nutritional
stress lead to antitoxin degradation and toxin activation. A
widespread toxin–antitoxin family consists of the ε/ζ
systems, which are distributed over plasmids and chromo-
somes of various pathogenic bacteria. In its inactive state,
the bacteriotoxic ζ toxin protein is inhibited by its cognate
antitoxin ε. Upon degradation of ε, the ζ toxin is released
allowing this enzyme to poison bacterial cell wall synthesis,
which eventually triggers autolysis. ε/ζ systems ensure
stable plasmid inheritance by inducing death in plasmid-
deprived offspring cells. In contrast, chromosomally
encoded ε/ζ systems were reported to contribute to
virulence of pathogenic bacteria, possibly by inducing
autolysis in individual cells under stressful conditions.
The capability of toxin–antitoxin systems to kill bacteria
has made them potential targets for new therapeutic
compounds. Toxin activation could be hijacked to induce
suicide of bacteria. Likewise, the unique mechanism of ζ
toxins could serve as template for new drugs. Contrarily,
inhibition of virulence-associated ζ toxins might attenuate
infections. Here we provide an overview of ε/ζ toxin–
antitoxin family and its potential role in the development of
new therapeutic approaches in microbial defense.
Keywords Antimicrobial peptides.Biochemistry.Cell
death.Drug development.Drug resistance.Infectiology
Introduction
The genomes of bacteria contain many mobile genetic
elements (MGEs) such as transposons, plasmids, or
bacteriophages that have been acquired by horizontal gene
transfer (HGT). Many MGEs serve as shuttles for genes
that are beneficial to bacteria during proliferation in a host
environment or in soil. Several supportive MGEs were
found in the genome of pathogenic bacteria and encode for
genes conferring antibiotic resistance and virulence factors
such as exotoxins, adhesins, and secretion systems [1–3].
However, this additional genetic material imposes a
metabolic burden to the bacterium. Thus, genes acquired
by HGT are prone to elimination from bacterial genomes in
absence of selective pressure [4]. To prevent removal,
MGEs contain maintenance systems that maximize their
retention within a bacterial population [5–7]. The most
abundant group of such stabilization systems are proteina-
ceous type II toxin–antitoxin (TA) systems. Initially, these
systems were identified as maintenance elements of con-
jugable low-copy number plasmids insuring stable inheri-
tance by a simple but effective mechanism [8–10]. Once a
plasmid encoding a TA system has been acquired, the host
bacterium starts to express two gene products from the TA
operon: a “toxin” protein that threatens to poison the host
from within and a cognate “antitoxin” protein that
inactivates the toxin by complex formation. When sufficient
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TA system. However, the antitoxin protein is prone to faster
degradation by intracellular proteases than the toxin. If
offspring loose the plasmid encoding for the TA system
during cell division, the continuous depletion of inherited
antitoxin protein causes release of the residual cytosolic
toxin. Eventually, the toxin triggers post-segregational
killing (PSK) of the host, since such a plasmid-free
bacterium would otherwise be favored when competing
with the metabolically handicapped plasmid-bearing
cells. A similar genome maintenance function was also
reported for chromosomally encoded type II TA systems
[7, 11]. Apart from that, it is emerging that several
bacterial species use TA systems for their own benefit
[12–14] and some TA systems were reported to be
involved in bacterial stress response [15, 16], protection
against PSK [17], phage exclusion [18, 19], differentiation
[20], and virulence [21, 22]. Yet, some of these proposed
functions such as a role of TA systems in bacterial stress
response are still a matter of ongoing debate due to a lack
of sufficient supportive data [23].
A TA element commonly found in multiresistance
plasmids and chromosomes of various human pathogens
are the ε/ζ systems. Whereas plasmid-encoded ε/ζ systems
ensure stable inheritance of plasmids, chromosomally
encoded homologues were reported to contribute to
virulence of pathogens. The recently uncovered mechanism
of ζ toxins sheds new light on these different functions of
the ε/ζ systems. Moreover, the unique enzymatic mecha-
nism of the ζ toxins provides new targets for the
development of novel antibiotics.
Cell killing by ζ toxins
As in other type II TA systems, the bacteriotoxic ζ protein
normallyresidesdormantinthecytosolofbacteriaincomplex
with ε. However, once the levels of ε decrease, for instance
when de novo expression is impaired, inhibition of ζ fails and
the toxin exerts its poisonous activity [24, 25]. Until recently,
the bacteriotoxic mechanism of ζ toxins has remained
elusive. Structural and mutational studies of the ε/ζ system
from Streptococcus pyogenes and pneumococcal ε/ζ antitox-
in–toxin (PezAT) from Streptococcus pneumoniae suggested
that ζ toxins might be kinases that phosphorylate an
enigmatic target under consumption of ATP [26–28].
This hypothesis was based on the structure of the ζ toxins,
since ζ resembles nucleoside monophosphate kinases and
polynucleotide kinases and mutations of putative catalyt-
ically important residues rendered the toxins inactive [28,
29]. Moreover, antitoxins occlude the proposed ATP-
binding site of ζ toxins and thereby inactivate the toxins
within the complexes.
First hints for deciphering the functional mechanism
of ζ toxins came from an in vivo study by Zielenkiewicz
and Ceglowski who showed that ζ is bactericidal in the
gram-positive Bacillus subtilis and causes growth arrest
and filamentation in the gram-negative Escherichia coli
[25]. Furthermore, an attenuated ζ variant was shown to
inhibit cell proliferation, causing cell lysis of a subpopu-
lation in B. subtilis [24]. In addition, Lioy et al. found that
elevated expression of ζ in E. coli causes a pleiotropic
inhibition of DNA replication, transcription, and transla-
tion without specifically targeting any of these cellular
events.
Recently, we deciphered the molecular mechanism of ζ-
induced cell death using the chromosomally encoded ζ
toxin PezT [30]. Expression of an attenuated PezT variant
in E. coli caused a phenotype like that observed during
treatment with β-lactam antibiotics. Cytosolic levels of
PezT inhibited binary fission and caused formation of mid-
cell positioned bulges, which eventually burst and lead to
cell death (Fig. 1a). We showed that ζ toxins specifically
phosphorylate the peptidoglycan precursor UDP-N-acetyl-
glucosamine (UNAG) at the 3′-OH group of the N-
acetylglucosamine moiety and thus define a new family of
small-molecule kinases (Fig. 1b) .T h et o x i cr e a c t i o n
product, UDP-N-acetylglucosamine-3-phosphate (UNAG-
3P), accumulates in the cytosol and competitively inhibits
MurA. Since MurA is the essential enzyme that catalyzes
the first committed step of peptidoglycan synthesis [31],
UNAG-3P thereby impairs the entire pathway (Fig. 1c).
The key residues for UNAG phosphorylation are well
conserved in ζ homologues from other bacteria (Fig. 2),
and we could indeed verify the UNAG kinase activity for
plasmid-borne ζ toxin. Thus, formation of UNAG-3P is
also the cause for PSK induced by plasmid-stabilizing ε/ζ
systems.
Plasmid-borne ε/ζ systems
ε/ζ systems encoded on plasmids of gram-positive
pathogens
The plasmid-borne ε/ζ system was originally discovered on
the low-copy number plasmid pSM19035 from a clinical
isolate of the gram-positive pathogen S. pyogenes [32]. This
plasmid confers resistances to high levels of erythromycin
and lincomycins [33] and is member of the broad host
family of Inc18-like plasmids. Although pSM19035 has a
low-copy number (two to five plasmids per cell [34]), it is
maintained in absence of any selective antibiotic. This
stable inheritance is conferred by plasmid-encoded segre-
gation (seg) loci, whose gene products control the plasmid
copy number, improve plasmid partitioning after replica-
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division, and trigger PSK (see Lioy et al. [6]). Among those
different maintenance mechanisms, PSK leading to suicide
of plasmid-devoid offspring primarily contributes to stable
inheritance of pSM19035 [25]. PSK is evoked by the segB1
locus that encodes three proteins: ω, a global transcription
repressor of pSM19035, the ε antitoxin, and the ζ toxin [32,
35] (Fig. 3a). The proteins ε and ζ are translated from a
bicistronic ε–ζ mRNA, whose transcription is regulated by
the ω repressor [36]. Upon plasmid loss, the pool of
proteolytically unstable ε antitoxin is eliminated by ATP-
dependent proteases and the released ζ prevents further
proliferation of plasmid-free cells [24, 25, 37].
More recently, a plethora of homologous ω–ε–ζ loci
were identified on multiple resistance plasmids of other
gram-positive pathogens such as Enterococcus faecalis and
Enterococcus faecium [38–43]o rStreptococcus agalactiae
[44]. Some of these ω–ε–ζ loci evoke stabilization of
conjugable Inc18-like plasmids that encode for the vanco-
mycin and teicoplanin resistance determinant vanA in
enterococci. Importantly, such Inc18-like plasmids were
not exclusively found in hospital strains but also in
common human community and animal-derived
vancomycin-resistant enterococci (VRE) strains [45, 46].
This suggests that these glycopeptide-resistant enterococci
propagate within the food chain. VRE strains are capable
Fig. 1 Bacteriotoxic mechanism
of ζ toxins. a Cytosolically
expressed ζ toxins in E. coli cause
inhibition of binary fission, mem-
brane bulge formation, and even-
tually autolysis. b ζ toxins
catalyze the ATP-dependent phos-
phorylation of the nucleotide sug-
ar UDP-N-acetylglucosamine
(UNAG)a tt h e3 ′-OH of the N-
acetylglucosamine moiety produc-
ing UDP-N-acetylglucosamine-3-
phosphate (UNAG-3P). c This
reaction introduces a detrimental
side branch to bacterial peptido-
glycan synthesis. UNAG is the
universal precursor of the sugar
backbone of the peptidoglycan
macromolecule, and normally, a
large fraction of the nucleotide
sugar is converted into UDP-N-
acetyl muramic acid (UDP-Mur-
NAc) through modification at the
3′-end of UNAG. The processing
of the UNAG 3′-OH involves an
enolpyruvyl transfer from phop-
sphoenolpyruvate (PEP) catalyzed
by MurA, which is followed by
an NADH-dependent reduction
catalyzed by MurB. This step
prepares UNAG for the subse-
quent addition of the muropeptide.
However, the phosphorylation of
UNAG by ζ converts the former
product of MurA into a competi-
tive inhibitor that blocks cell wall
synthesis. In the presence of the
antitoxin ε, however, the kinase
activity of ζ is inhibited
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methicillin-resistant Staphylococcus aureus (MRSA) [47–
50], and it is conceivable that ε/ζ systems also participate
in the stable persistence of vanA in the resulting
vancomycin-resistant S. aureus strains, which has evolved
to a major public health concern.
A thorough sequence analysis divided ε/ζ systems into
two distinct phylogenetic groups that differed in their
efficiency to stabilize plasmids in E. faecalis [42, 43].
Notably, these two different groups show sequence varia-
tion in the ε and ζ protein interface [28, 43] but are
conserved in the active site of ζ. This suggests that fine-
tuning of the ε–ζ affinity is crucial for the efficiency of
plasmid stabilization and is an evolved, host-adaptive
feature.
ε/ζ systems encoded on plasmids of gram-negative bacteria
Originally, ε/ζ s y s t e m sw e r ep r e s u m e dt ob ec o n f i n e dt o
gram-positive bacteria but were recently identified on
IncP1 plasmids of Neisseria gonorrhoeae isolates from
American and Dutch patients [14, 51]. Within the
tetracycline determinant tetM of these plasmids, two
different ε/ζ loci were identified, but no open reading
frame (ORF) for an ω homologue was found. This
suggests that the ε/ζ system from IncP1 plasmids is
regulated differently when compared with those found in
Inc18-like plasmids. ORFs encoding for ε/ζ systems were
further identified on resistance plasmids in Bacteroides
fragilis [52]. A recent phylogenetic analysis of type II TA
systems suggested that homologues of ε/ζ systems are
widespread in all bacterial kingdoms [53]. This study also
showed that most ζ toxins reside on bacterial chromo-
somes rather than plasmids.
Chromosomal ε/ζ systems
The PezAT system from S. pneumoniae
The human pathogen S. pneumoniae is one of the leading
causes for bacterial pneumonia, otitis media, and invasive
disease such as bacteremia and meningitis. More than 90
different pneumococcal serotypes have been classified [54]
which differ strongly in their virulence. However, only a
limited number of ∼16 serotypes are found worldwide to
cause the bulk of invasive diseases [55, 56]. Since a strong
variation in virulence was reported for strains belonging to
identical serotypes, the content of the polysaccharide
capsule is not the main and exclusive determinant for
pathogenicity [57–59]. Differences in virulence result rather
from genomic heterogeneity caused by variable regions in
the genome of S. pneumoniae. Genes in these accessory
regions encode important virulence factors such as adhesion
factors, transporters, and metabolic enzymes [58, 60–62].
The chromosomally encoded ζ homologue PezT (Fig. 2)i s
expressed from the bicistronic pezAT operon (locus tag:
SP1050/SP1051) located on the pneumococcal pathogenic-
ity island PPI-1 [21, 59, 63] and, most importantly, was
shown to be required to establish full virulence in mice
[21]. However, unlike the otherwise stably integrated and
conserved PPI region, the pezAT operon resides in the
recombination hot-spot PPI-1v that is highly diverse in its
gene content [59]. Similar to the plasmid-borne ε/ζ
systems, the bacteriotoxic UNAG kinase activity of PezT
was shown to be inhibited by high-affinity binding of the
antitoxin PezA [28, 64]. In contrast to plasmid-borne ε/ζ
systems whose expression relies on the ω repressor, PezA
harbors a transcription repressor domain in addition to its ε
homology domain (Fig. 3b).
The contribution of PezT to pneumococcal virulence
A major step in connecting PezT with virulence in S.
pneumoniae came from the work by Brown et al. who
compared clinical serotype 3 isolates with PezT knockout
strains in mixed systemic and respiratory infections of mice
[21]. The authors showed that disruption of the PezT ORF
resulted in a variant that was outcompeted by wild-type
strains in mouse challenge models. Only a single isolate out
of 500 that were recovered from mice either 24 h after
systemic infections or 72 h after respiratory infections
contained a disrupted PezT ORF. Furthermore, a consider-
ably attenuated infection progress in mice was observed
when strains deprived of the PezT ORF were compared
with wild-type strains. However, PezT-negative strains had
no growth defect in laboratory broth, serum, or blood. This
demonstrated that the phenotype of PezT disruption is
virulence specific and not a general growth defect. Along
Fig. 2 Sequence alignment of representative ζ toxins from gram-
positive and gram-negative bacteria. The NCBI accession numbers are
given in brackets. S. pneumoniae (NP_345525), S. agalactiae
(NP_735780), Oribacterium sinus (ZP_03991854), Eggerthella lenta
(YP_003180798), E. faecalis (ZP_07107801), S. pyogenes
(YP_232762), Lactobacillus antri (ZP_05746663), Bacillus fusiformis
(ZP_07050953), E. coli O103:H2 (NC_013353), Neisseria cinerea
(ZP_05983406), Bacteroides intestinalis (ZP_03012857), and Capno-
cytophaga ochracea (YP_003140484). Identical residues are colored
in dark green and according to the decreasing similarity from light
green through orange to yellow. Secondary structure elements of ζ
from S. pyogenes are shown above the sequence. Note that 71 N-
terminal residues of the E. coli sequence were omitted from the
alignment, and some sequences were truncated at their C-terminus.
Squares indicate those residues involved in the interaction with
UNAG in the ζ from S. pyogenes. Diamonds indicate those residues
whose mutation by site-directed mutagenesis in PezT and ζ from S.
pyogenes were shown to abolish toxicity. The conserved Walker A
motif that is crucial for ATP binding is marked in pink, and the loop
region forming contacts to the UNAG phosphates is marked in blue

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isolates from indigenous Australian patients revealed that
the pezAT ORF was exclusively contained in the recombi-
nation hot-spot PPI-1v of hypervirulent isolates, whereas it
was absent in the PPI-1v of noninvasive and intermediately
virulent strains [59]. Similar to as found by Brown et al.,
these hypervirulent strains caused rapid lethal infection in
intranasally challenged mice, whereas the infection prog-
ress of the pezAT-negative, intermediately virulent isolates
was strongly attenuated. Furthermore, when the pezAT-
positive PPI-1v element of the virulent laboratory S.
pneumoniae D39 strain was replaced by a pezAT-negative
PPI-1v element from a noninvasive isolate, this hybrid
strain was readily outcompeted by wild-type strains in nasal
lavage fluid, lungs, and blood models [59]. In contrast,
replacing the D39 PPI-1v with one from the hypervirulent
serotype 1 isolates resulted in a hybrid strain that was as
effective in infection as the wild-type strain. It is notewor-
thy that the occurrence of pezAT locus is not the only
difference within the gene content of these PPI-1v regions
[59]. Thus, the increased pathogenicity of pezAT-positive
PPI-v regions does not unambiguously demonstrate that
pezAT is the exclusive virulence factor within PPI-1v.
Nonetheless, its exclusive occurrence in hypervirulent
strains is striking.
The strong correlation of pezAT loci in PPI-1v and
occurrence of hypervirulence suggests that the bacteria
have taken advantage of the TA system to increase the
speed of infection. It is rather unlikely that PezAT is a
simple maintenance system of PPI-1v, since despite the
pezAT locus, the other gene content of PPI-1v is highly
variable. More likely, the originally as being detrimental
perceived UNAG kinase activity of PezT could support
pneumococcal virulence directly. PezT might be released
Fig. 3 Operon architecture of the plasmid-borne ε/ζ systems and the
chromosomal PezAT system. a Architecture of the ω/ε/ζ operon that
stabilizes multiresistance plasmids in a broad range of bacteria. The
ω/ε/ζ operon contains the two discrete promoters Pω and Pε.P ω
produces transcripts containing either the ω, the ω/ε, or the ω/ε/ζ
ORFs and is auto-repressed by ω (yellow). Pε is a weak constitutive
promoter that produces transcripts containing the ORFs of ε alone or
ε/ζ. The antitoxin ε (blue) and the toxin ζ (red) proteins form an
inactive complex after translation. In case the encoding plasmid is lost,
ζ is released from the ε/ζ complex through continuous degradation of
ε by constitutive proteases. b Organization of the pezAT operon from
S. pneumoniae. In contrast to the ω/ε/ζ system, no ω operon is
present and autoregulation of the operon is achieved by the antitoxin
PezA (blue) with the toxin PezT (red) acting as corepressor. Similar to
ε/ζ, PezA and PezT form a stable complex. When and how the toxin
PezT is released from the PezAT complex is unknown
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nutrients, presence of antibiotics, or the immune response,
as observed for other TA systems [16, 65–67]. In this
scenario, UNAG-3P production would result in inhibition
of cell wall synthesis and lysis of a pneumococcal
subpopulation. The ability to undergo lysis under stress
conditions is a peculiar feature of pneumococci. It is
evoked either by self-induced autolysis [68, 69]o rb y
fratricide, in which competent cells induce lysis of their
noncompetent sister cells [70]. Generally, lysis of gram-
positive bacteria has great impact on virulence, since it
leads to accelerated release of cellular components that are
detrimental to the infected host. Components which are
well established as virulence factors are teichoic acids,
lipoteichoic acids, and bacterial DNA [71]. In addition,
cell fragments from lysed pneumococci inhibit phagocy-
tosis and impair phagocyte-mediated defense against
living pneumococci [72]. Most importantly, pneumococcal
lysis leads to triggered release of pneumolysin (Ply),
which has multiple detrimental effects for the host
organism (see [73]). Low Ply concentrations are already
sufficient to trigger apoptosis [74], to activate host
complement [75], and to induce proinflammatory reac-
tions [76]. At elevated concentrations, Ply causes general
cellular damage in the host organism by its cholesterol-
dependent ability to form large membrane pores [77].
However, unlike other bacterial exotoxins, Ply is not
directly secreted into the bacteria environment and its
release relies on pneumococcal lysis after peptidoglycan
degradation as, for example, caused by the major
pneumococcal autolysin LytA [78], and similar to PezT,
impairment of Ply and LytA function also causes attenu-
ated virulence in infection models [79–82]. Thus, it is
likely that PezT indeed supports pneumococcal lysis
causing cellular fragmentation and by triggered release
of virulence factors.
A remaining conundrum is how activation of PezT is
accomplished during infection, since PezA and PezT
establish an extremely tight complex and house-keeping
proteases of E. coli and B. subtilis were unable to
disassemble this complex [64]. This implies that a specific
pneumococcal protease or protease adaptor protein is
required to remove and degrade PezA from PezT. More
experimental data are required to decipher the molecular
mechanisms of PezAT's contribution to pneumococcal
virulence. Likewise, the role of PezAT homologues in other
streptococcal pathogens such as S. agalactiae and Strepto-
coccus suis [63] remains completely unexplored. Moreover,
the presence of ζ homologues in the chromosomes of
pathogenic E. coli and Capnocytophaga strains (Fig. 3)
raises interesting questions about a general implication of
the UNAG kinases family in virulence of gram-negative
pathogens.
ζ toxins in drug development
Specific activation of ζ toxins
Drugs that disrupt normal operation of TA systems (Fig. 4a)
are considered an attractive target for development of new
therapeutic agents [83–85]. Pathogenic species could be
specifically affected, without eliminating the bulk of the
mutualistic bacterial flora. On the one hand, compounds
could be developed that directly interfere with toxin
inhibition by the antitoxin such as for instance disrupting
the TA interaction [85] (Fig. 4b). On the other hand,
specific compounds that impair expression of a TA
operon could trigger toxin release indirectly (Fig. 4c).
In fact, interference with antitoxin inhibition seems to be
explored by bacteria themselves. The quorum-sensing
pentapeptide extracellular death factor (EDF) has been
shown to stimulate the MazF endoribonuclease of the
chromosomal MazEF system [86]. Although the antitoxin
MazE is present, the endoribunclease activity is enhanced
by EDF and this is thought to trigger stress-induced cell
death in E. coli [86].
Similarly, an artificial disruption of the toxin–antitoxin
interaction of the ε/ζ TA system from S. pyogenes has
recently been described [87]. In a high-throughput ap-
proach, a mixture of oligopeptide libraries was screened for
their ability to impair the ε–ζ interaction. Thereby, sub-
libraries containing 17 amino acids long peptides were
shown to interfere with the ε–ζ interaction. However,
further subfractionation of this mixed oligopeptide libraries
lead to loss of this capability and the authors suggested
that avidity effects from several weak binders could have
caused disruption of the protein interaction [87]. It
remains to be shown whether those peptide inhibitors
can also restore UNAG kinase activity of ζ, as they could
block the ATP binding similarly as the antitoxin ε does.
Whether dismantling of the ε–ζ interaction is always
feasible remains questionable, since this relies heavily on
the dissociation kinetics of the complex. For instance,
dissociation of the ultra-tight PezAT complex is extremely
slow, rendering it difficult to disrupt the complex by any
peptide inhibitor [64].
Another very promising approach to achieve ζ activation
and toxins of other TA systems directly is interference with
de novo synthesis by use of antisense RNA mechanisms
(Fig. 4c). This would provoke specific degradation of the
TA mRNA and thereby impair de novo synthesis of the TA
proteins. For instance, such successful knockdowns of
genes essential for bacterial viability were achieved by
liposome-delivered antisense RNA [88] or peptide nucleic
acids [89–92].
It remains to be shown whether ζ or PezT activation is
indeed always a beneficial approach for microbial defense. In
J Mol Med (2011) 89:1183–1194 1189cases where the TA system is associated with virulence,
activation of the toxin could increase infectiousness by
enhanced cell lysis and boosted virulence factor release from
the pathogenic bacteria. In this case, an as-yet-unknown but
specific inhibitor of ζ toxin itself would be expected to
eliminate the toxic effects of the TA system (Fig. 4d).
UNAG-3P in drug development
The enzymatic product of this kinase family, UNAG-3P, is a
promising lead compound for the development of a new
broad-spectrum antibiotic. UNAG-3P inhibits MurA [30]
and most likely also its paralogue MurZ, which are
conserved enzymes in peptidoglycan synthesis in all
gram-positive and gram-negative bacteria. This family of
enzymes is an attractive drug target for microbial defense,
since no eukaryotic homolog exists [93]. However, apart
from the naturally occurring, broad-spectrum antibiotic
fosfomycin, no specific MurA inhibitors have been applied
so far [94]. Because an increasing number of bacteria have
developed resistance, fosfomycin has turned into a rela-
tively inefficient drug [94]. Thus, the discovery of UNAG-
3P discloses a novel and attractive compound that has the
potential to evolve into a drug inhibiting MurA.
Moreover, UNAG-3P most likely interferes with
bacterial biosynthetic pathways of other glycoconjugates
as well. For instance, formation of UNAG-3P might
interfere with lipopolysaccharide (LP) production in
gram-negative bacteria. LP biosynthesis requires the
unique and distinctive building block lipid A. This
phosphoglycolipid is highly conserved [95], and its
formation is initiated by condensation of the 3′-OH group
of the N-acetylglucosamine moiety of UNAG with a lipid
anchor [96]. It remains to be shown for this pathway
whether UNAG-3P is an inhibitor similar as it is for
peptidoglycan synthesis or is just a dead-end nucleotide
sugar. LPs are part of the outer membrane of gram-
negative bacteria and protect bacterial cells from cell-
damaging agents. Moreover, LPs act as endotoxins and
can cause septic shocks due to stimulation of excessive
levels of proinflammatory cytokines [97]. Thus, UNAG-
3P could not only impair bacterial growth but could also
reduce LP-induced toxic shock responses during infection.
Moreover, teichoic acids, which are diverse multifunc-
tional glycopolymers that reside in the cell wall of gram-
positive bacteria, require UNAG as precursor. Similar to
inhibition of teichoic acid synthesis leading to bacteriostasis
[98] and impaired host colonization and tissue invasion in
Fig. 4 Different possibilities to
target TA systems. a In a ge-
nome maintenance TA system,
the excess production of the
labile antitoxin and its high
affinity to the toxin prevent cell
death. b An agent that would
shift the toxin–antitoxin equilib-
rium towards an active toxin
species, for example by masking
the toxin binding site of the
antitoxin, could trigger bacterial
cell death. c Likewise, any sup-
pression of de novo synthesis
from the TA operon as for
example by an mRNA antisense
mechanism would result in toxin
release as consequence of anti-
toxin degradation. d Chromo-
somal TA systems whose
function is beneficial for the
fitness of the bacterial popula-
tion are often also activated by
downregulation of de novo syn-
thesis, by upregulation of anti-
toxin degradation, or both
mechanisms in parallel. Howev-
er, a cellular activation of such a
TA system could be prevented
by specific inhibition of the
toxin activity
1190 J Mol Med (2011) 89:1183–1194MRSA [99], UNAG-3P might impair these bacterial
mechanisms as well.
The discovery of UNAG-3P as a new natural product
has uncovered the basic principles for the development of a
new broad-spectrum antibiotic, and new challenges need to
be managed to turn it into an effective drug. An obvious
and required improvement is to render this compound
permeable for cell membranes. UNAG-3P is a highly
charged anionic molecule and thus most likely will not
penetrate through membranes. Further synthetic modifica-
tions of UNAG-3P should aim at creating membrane-
permeable derivates of UNAG-3P and probe their activity
against gram-positive and gram-negative bacteria. For
instance, reversible masking of the phosphate groups
should help to reduce the permeability barrier [100, 101].
Furthermore, it remains unclear whether UNAG-3P has
any detrimental effect on eukaryotes, since UNAG is also
an essential metabolite for these organisms. Previous
studies have shown that ectopic expression of ζ from S.
pyogenes in Saccharomyces cerevisiae caused growth
retardation, albeit the general toxicity of ζ was much
weaker when compared with the bacteria [102]. This
growth retardation in yeast might be explained by a toxic
effect of UNAG-3P. However, a more likely explanation is
an artificial depletion of cells from UNAG by ζ's enzymatic
activity. Cytosolic concentrations of UNAG are approxi-
mately 10 times lower in S. cerevisiae (∼30 μM) than in E.
coli [103], and a rapid depletion of UNAG by ζ will most
probably impair chitin synthesis in S. cerevisiae [104].
Although UNAG-3P is a very promising lead compound
for drug development, it might also have undesired adverse
reactions similar to those of other lytic antibiotics when
detrimental effects upon endotoxin release have to be
expected [105].
Inhibition of PezT
Both triggered induction of cell death upon treatment with
UNAG-3P-derived drugs or upon activation of PezT toxins
will boost the release of virulence factors from pathogenic
bacteria into their environment. The involvement of PezT
toxins in virulence makes it conceivable that an attenuation
of fulminant pneumococcal infections could be achieved by
the inhibition of PezT's lytic activity. If the increase of the
survival time during fulminant infections in humans is
similar to what was observed after PezT inactivation in
mice, such an inhibitor could help to increase the time
window for therapeutic intervention and allow a retarded
kill-off of pathogens.
Another interesting, although still speculative, aspect
of PezT's contribution to virulence is a possible involve-
ment as endotoxin during infection. Similar to the
cytolysin-mediated translocation of the toxic S. pyogenes
NAD glycohydrolase into host cells [106], PezT could
enter the cytosol of the infected host cells. In this
scenario, PezT would aggravate eukaryotic cells by its
fatal enzymatic mechanism similarly as observed during
ectopic expression in S. cerevisiae [102]. A PezT
inhibitor that enters eukaryotic cells as well would have
dual function and could not only counteract pneumococcal
autolysis but additionally abolish the toxin's activity in the
infected host.
Conclusion
The recent discovery of the UNAG kinase activity of ζ
toxins and its implementation in programmed cell death
has expanded the repertoire of cellular structures
targeted by TA systems to include corruption of cell
wall synthesis. Whereas all other type II TA systems
either interfere with replication or translation [13, 14], ζ
toxins are the first reported inhibitors of peptidoglycan
synthesis and most probably of other biosynthetic path-
ways involved in cell wall synthesis as well. Thus, the list
of cellular structures targeted by TA systems becomes
more complete and TA systems seem to impair the same
cellular mechanisms that commonly applied antibiotics
target as well. Exploring especially ε/ζ TA systems in our
microbial defense is a promising approach, since this
system provides several important points of attack that can
be targeted by drugs. Furthermore, any compound inter-
fering with this element will be of general impact, since
loci encoding for ε/ζ systems are widely distributed
among pathogenic bacteria.
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